Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/immune-responses-against-severe-acute-respiratory-syndrome-coronavirus-V0mV4KeTMX
References (29)
-
Yue Huang, Zhi-yong Yang, W. Kong, G. Nabel (2004)
Generation of Synthetic Severe Acute Respiratory Syndrome Coronavirus Pseudoparticles: Implications for Assembly and Vaccine ProductionJournal of Virology, 78
-
Zhimin Zhou, Penny Post, R. Chubet, Kathy Holtz, Clifton McPherson, M. Petric, M. Cox (2006)
A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in miceVaccine, 24
-
L. Kuo, P. Masters (2003)
The Small Envelope Protein E Is Not Essential for Murine Coronavirus ReplicationJournal of Virology, 77
-
T. Ksiazek, D. Erdman, C. Goldsmith, S. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J. Comer, W. Lim, P. Rollin, S. Dowell, A. Ling, C. Humphrey, W. Shieh, J. Guarner, C. Paddock, P. Rota, B. Fields, J. Derisi, J. Yang, N. Cox, J. Hughes, J. Leduc, W. Bellini, L. Anderson (2003)
A novel coronavirus associated with severe acute respiratory syndrome.The New England journal of medicine, 348 20
-
P. Baudoux, C. Carrat, L. Besnardeau, B. Charley, H. Laude (1998)
Coronavirus Pseudoparticles Formed with Recombinant M and E Proteins Induce Alpha Interferon Synthesis by LeukocytesJournal of Virology, 72
-
J. Galarza, Theresa Latham, A. Cupo (2005)
Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.Viral immunology, 18 1
-
C. O’Neal, J. Clements, M. Estes, M. Conner (1998)
Rotavirus 2/6 Viruslike Particles Administered Intranasally with Cholera Toxin, Escherichia coli Heat-Labile Toxin (LT), and LT-R192G Induce Protection from Rotavirus ChallengeJournal of Virology, 72
-
L. Du, Yuxian He, Yi-jia Wang, Haojie Zhang, S. Ma, C. Wong, S. Wu, F. Ng, Jian-Dong Huang, K. Yuen, Shibo Jiang, Yusen Zhou, B. Zheng (2006)
Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccinesVirology, 353
-
C. Haan, L. Kuo, P. Masters, H. Vennema, P. Rottier (1998)
Coronavirus Particle Assembly: Primary Structure Requirements of the Membrane ProteinJournal of Virology, 72
-
P. Pushko, T. Tumpey, Fang-tian Bu, J. Knell, Robin Robinson, Gale Smith (2005)
Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.Vaccine, 23 50
-
P. Rota, M. Oberste, S. Monroe, W. Nix, R. Campagnoli, J. Icenogle, Silvia Peñaranda, B. Bankamp, K. Maher, Min-Hsin Chen, Suxiong Tong, A. Tamin, Luis Lowe, M. Frace, J. Derisi, Qi Chen, David Wang, D. Erdman, T. Peret, C. Burns, T. Ksiazek, P. Rollin, A. Sanchez, Stephanie Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Günther, A. Osterhaus, C. Drosten, M. Pallansch, L. Anderson, W. Bellini (2003)
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory SyndromeScience, 300
-
Tsanan Giroglou, J. Cinatl, H. Rabenau, C. Drosten, H. Schwalbe, H. Doerr, D. Laer (2004)
Retroviral Vectors Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S ProteinJournal of Virology, 78
-
Yuxian He, Jingjing Li, S. Heck, S. Lustigman, Shibo Jiang (2006)
Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine DesignJournal of Virology, 80
-
C. Drosten, S. Günther, W. Preiser, S. Werf, H. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R. Fouchier, A. Berger, A. Burguière, J. Cinatl, M. Eickmann, N. Escriou, Klaus Grywna, S. Kramme, J. Manuguerra, S. Müller, V. Rickerts, M. Stürmer, Simon Vieth, H. Klenk, A. Osterhaus, H. Schmitz, H. Doerr (2003)
Identification of a novel coronavirus in patients with severe acute respiratory syndrome.The New England journal of medicine, 348 20
-
E. Corse, C. Machamer (2000)
Infectious Bronchitis Virus E Protein Is Targeted to the Golgi Complex and Directs Release of Virus-Like ParticlesJournal of Virology, 74
-
Wenhui Li, M. Moore, N. Vasilieva, J. Sui, S. Wong, M. Berne, M. Somasundaran, J. Sullivan, K. Luzuriaga, T. Greenough, H. Choe, M. Farzan (2004)
What’s new in the renin-angiotensin system?Cellular and Molecular Life Sciences, 61
-
S. Jeong, M. Qiao, M. Nascimbeni, Zongyi Hu, B. Rehermann, K. Murthy, T. Liang (2004)
Immunization with Hepatitis C Virus-Like Particles Induces Humoral and Cellular Immune Responses in Nonhuman PrimatesJournal of Virology, 78
-
L. Koutsky, K. Ault, C. Wheeler, Darron Brown, E. Barr, F. Alvarez, L. Chiacchierini, K. Jansen (2002)
A controlled trial of a human papillomavirus type 16 vaccine.The New England journal of medicine, 347 21
-
J. Peiris, S. Lai, L. Poon, Y. Guan, L. Yam, W. Lim, J. Nicholls, W. Yee, W. Yan, M. Cheung, V. Cheng, K. Chan, D. Tsang, R. Yung, T. Ng, K. Yuen (2003)
Coronavirus as a possible cause of severe acute respiratory syndromeLancet (London, England), 361
-
A. Bonavia, B. Zelus, D. Wentworth, P. Talbot, K. Holmes (2003)
Identification of a Receptor-Binding Domain of the Spike Glycoprotein of Human Coronavirus HCoV-229EJournal of Virology, 77
-
Li Li, Moore Moore, Vasilieva Vasilieva (2003)
Angiostensin‐converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 426
-
G. Babcock, Diana Esshaki, W. Thomas, D. Ambrosino (2004)
Amino Acids 270 to 510 of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Are Required for Interaction with ReceptorJournal of Virology, 78
-
M. Spruth, O. Kistner, H. Savidis-Dacho, Elisabeth Hitter, B. Crowe, M. Gerenčer, P. Brühl, L. Grillberger, M. Reiter, C. Tauer, W. Mundt, P. Barrett (2005)
A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responsesVaccine, 24
-
Thomas Evans, W. Bonnez, R. Rose, S. Koenig, L. Demeter, J. Suzich, D. O'Brien, Meredith Campbell, W. White, J. Balsley, R. Reichman (2001)
A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.The Journal of infectious diseases, 183 10
-
H. Kubo, Yasuko Yamada, Fumihiro, Taguchi (1994)
Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike proteinJournal of Virology, 68
-
Yu Ho, P. Lin, C. Liu, Su-Ping Lee, Y. Chao (2004)
Assembly of human severe acute respiratory syndrome coronavirus-like particlesBiochemical and Biophysical Research Communications, 318
-
P. Roy, P. Roy, P. Roy, D. Bishop, H. Leblois, H. Leblois, B. Erasmus (1994)
Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.Vaccine, 12 9
-
Milan Surjit, Bo-ping Liu, Purnima Kumar, V. Chow, S. Lal (2004)
The nucleocapsid protein of the SARS coronavirus is capable of self-association through a C-terminal 209 amino acid interaction domain☆Biochemical and Biophysical Research Communications, 317
-
M. Marra, Steven Jones, C. Astell, R. Holt, A. Brooks-Wilson, Y. Butterfield, J. Khattra, J. Asano, Sarah Barber, Susanna Chan, A. Cloutier, S. Coughlin, Doug Freeman, Noreen Girn, O. Griffith, S. Leach, Michael Mayo, H. McDonald, S. Montgomery, P. Pandoh, A. Petrescu, A. Robertson, J. Schein, Asim Siddiqui, D. Smailus, J. Stott, George Yang, Francis Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T. Booth, Donnie Bowness, M. Czub, M. Drebot, Lisa Fernando, R. Flick, M. Garbutt, Michael Gray, A. Grolla, Steven Jones, H. Feldmann, A. Meyers, A. Kabani, Yan Li, Susan Normand, Ute Stroher, G. Tipples, S. Tyler, Robert Vogrig, D. Ward, Brynn Watson, R. Brunham, M. Krajden, M. Petric, D. Skowronski, C. Upton, R. Roper (2003)
The Genome Sequence of the SARS-Associated CoronavirusScience, 300
- Publisher
- Wiley
- Copyright
- Copyright © 2007 Wiley Subscription Services, Inc., A Wiley Company
- ISSN
- 0019-2805
- eISSN
- 1365-2567
- DOI
- 10.1111/j.1365-2567.2007.02676.x
- pmid
- 17680799
- Publisher site
- See Article on Publisher Site
Abstract
Summary Virus‐like particles (VLPs) represent a promising vaccine against severe acute respiratory syndrome coronavirus (SARS CoV). In this study, recombinant baculovirus vAcS and vAcME were constructed to express the S protein and the M and E proteins of SARS CoV, respectively. Electron microscope analysis demonstrated the formation of VLPs in vAcME and vAcS coinfected insect cells. Mice immunized four times with VLPs developed high antibody titres against SARS CoV. In addition, VLPs elicited cell‐mediated immunity as demonstrated by enhanced interferon‐γ and interleukin‐4 production. VLPs also conferred protective immunity against the infection of Spike protein pseudotyped murine leukaemia virus. Our findings demonstrate that SARS CoV VLPs are immunogenic and can elicit strong SARS CoV‐specific humoral and cellular immune responses in mice. This is the first study describing the immunogenicity of SARS CoV VLPs, providing valuable data for developing a protective vaccine against SARS CoV infection.
Journal
Immunology – Wiley
Published: Dec 1, 2007